Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Overcoming barriers to referral for CAR-T cell therapy in R/R DLBCL

Marc Hoffmann • 10 Dec 2023
ASH 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

Marc Hoffmann, MD, The University of Kansas, Kansas City, KS, highlights the key barriers to referral, which have extended from transplantation to CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and have led to only around one-third of patients eligible for CAR-T receiving the treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Pharmacyclics LLC (an AbbVie Company)
Honoraria: Pharmacyclics LLC (an AbbVie Company)

More from Marc Hoffmann

1:48
Golcadomide, a novel CELMoD agent, with R-CHOP in patients with untreated a-BCL
Marc Hoffmann • 10 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals